Solomon Moshkevich Sells 6,000 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider Solomon Moshkevich sold 6,000 shares of the firm's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $143.29, for a total transaction of $859,740.00. Following the transaction, the insider now directly owns 143,768 shares in the company, valued at $20,600,516.72. The trade was a 4.01 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Solomon Moshkevich also recently made the following trade(s):

• On Wednesday, January 29th, Solomon Moshkevich sold 5,201 shares of Natera stock. The shares were sold at an average price of $165.87, for a total value of $862,689.87.
• On Wednesday, January 22nd, Solomon Moshkevich sold 24,861 shares of Natera stock. The stock was sold at an average price of $164.97, for a total value of $4,101,319.17.
• On Monday, December 9th, Solomon Moshkevich sold 4,858 shares of Natera stock. The shares were sold at an average price of $166.59, for a total value of $809,294.22.

Natera Price Performance

Shares of Natera stock traded up $7.39 on Tuesday, reaching $140.02. The stock had a trading volume of 2,219,493 shares, compared to its average volume of 1,336,563. The business's 50 day moving average is $165.10 and its two-hundred day moving average is $148.16. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. Natera, Inc. has a 1 year low of $83.13 and a 1 year high of $183.00. The company has a market cap of $18.93 billion, a P/E ratio of -79.56 and a beta of 1.80.

Remove Ads

Natera (NASDAQ:NTRA - Get Free Report) last posted its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.01. The business had revenue of $476.10 million for the quarter, compared to analysts' expectations of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. As a group, research analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Craig Hallum boosted their price target on shares of Natera from $121.00 to $157.00 and gave the stock a "buy" rating in a report on Wednesday, November 13th. Canaccord Genuity Group reissued a "buy" rating and set a $180.00 target price on shares of Natera in a research report on Wednesday, February 26th. Morgan Stanley lifted their price target on shares of Natera from $176.00 to $185.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. Sanford C. Bernstein upped their price objective on Natera from $160.00 to $200.00 and gave the company an "outperform" rating in a research note on Friday, January 10th. Finally, JPMorgan Chase & Co. raised their target price on Natera from $160.00 to $200.00 and gave the stock an "overweight" rating in a research report on Friday, December 13th. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $173.56.

Institutional Investors Weigh In On Natera

Several large investors have recently added to or reduced their stakes in NTRA. Chartwell Investment Partners LLC raised its holdings in shares of Natera by 37.9% in the 3rd quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company's stock valued at $5,243,000 after acquiring an additional 11,362 shares in the last quarter. Cerity Partners LLC raised its stake in Natera by 27.0% in the third quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company's stock valued at $10,936,000 after purchasing an additional 18,316 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in Natera in the third quarter valued at approximately $385,000. Everence Capital Management Inc. bought a new stake in Natera during the fourth quarter valued at approximately $573,000. Finally, Alpha DNA Investment Management LLC purchased a new position in Natera in the 3rd quarter worth approximately $505,000. Institutional investors own 99.90% of the company's stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.